| CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by … M Pfreundschuh, L Trümper, A Österborg, R Pettengell, M Trneny, K Imrie, ... The lancet oncology 7 (5), 379-391, 2006 | 2519 | 2006 |
| Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma JF San Miguel, R Schlag, NK Khuageva, MA Dimopoulos, O Shpilberg, ... New England Journal of Medicine 359 (9), 906-917, 2008 | 2461 | 2008 |
| Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era C Gisselbrecht, B Glass, N Mounier, D Singh Gill, DC Linch, M Trneny, ... Journal of Clinical Oncology 28 (27), 4184-4190, 2010 | 1733 | 2010 |
| Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. RH Collins Jr, O Shpilberg, WR Drobyski, DL Porter, S Giralt, R Champlin, ... Journal of clinical oncology 15 (2), 433-444, 1997 | 1555 | 1997 |
| Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up H Tilly, MG Da Silva, U Vitolo, A Jack, M Meignan, A Lopez-Guillermo, ... Annals of oncology 26, v116-v125, 2015 | 1072 | 2015 |
| CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the … M Pfreundschuh, E Kuhnt, L Trümper, A Österborg, M Trneny, L Shepherd, ... The lancet oncology 12 (11), 1013-1022, 2011 | 841 | 2011 |
| Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in … MV Mateos, PG Richardson, R Schlag, NK Khuageva, MA Dimopoulos, ... Journal of Clinical Oncology 28 (13), 2259-2266, 2010 | 568 | 2010 |
| Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously … JF San Miguel, R Schlag, NK Khuageva, MA Dimopoulos, O Shpilberg, ... Journal of clinical oncology 31 (4), 448-455, 2013 | 361 | 2013 |
| Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of … C Gisselbrecht, N Schmitz, N Mounier, D Singh Gill, DC Linch, M Trneny, ... Journal of Clinical Oncology 30 (36), 4462-4469, 2012 | 328 | 2012 |
| Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Dreyling, E Campo, O Hermine, M Jerkeman, S Le Gouill, S Rule, ... Annals of Oncology 28, iv62-iv71, 2017 | 302 | 2017 |
| Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study E Van Den Neste, N Schmitz, N Mounier, D Gill, D Linch, M Trneny, ... Bone marrow transplantation 51 (1), 51-57, 2016 | 286 | 2016 |
| Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era G Goyal, ML Heaney, M Collin, F Cohen-Aubart, A Vaglio, BH Durham, ... Blood, The Journal of the American Society of Hematology 135 (22), 1929-1945, 2020 | 253 | 2020 |
| Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or … M Pfreundschuh, AD Ho, E Cavallin-Stahl, M Wolf, R Pettengell, I Vasova, ... The lancet oncology 9 (5), 435-444, 2008 | 251 | 2008 |
| ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) M Ghielmini, U Vitolo, E Kimby, S Montoto, J Walewski, M Pfreundschuh, ... Annals of oncology 24 (3), 561-576, 2013 | 248 | 2013 |
| Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis B Rozen-Zvi, A Gafter-Gvili, M Paul, L Leibovici, O Shpilberg, U Gafter American Journal of Kidney Diseases 52 (5), 897-906, 2008 | 241 | 2008 |
| Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del (5q) myelodysplastic syndromes and ineligible for or … V Santini, A Almeida, A Giagounidis, S Gröpper, A Jonasova, N Vey, ... Journal of Clinical Oncology 34 (25), 2988-2996, 2016 | 237 | 2016 |
| Positron emission tomography–computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset … J Trotman, M Fournier, T Lamy, JF Seymour, A Sonet, A Janikova, ... Journal of Clinical Oncology 29 (23), 3194-3200, 2011 | 233 | 2011 |
| VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results … MA Dimopoulos, PG Richardson, R Schlag, NK Khuageva, O Shpilberg, ... Journal of Clinical Oncology 27 (36), 6086-6093, 2009 | 212 | 2009 |
| Role and prognostic significance of the Ki‐67 index in non‐Hodgkin's lymphoma A Broyde, O Boycov, Y Strenov, E Okon, O Shpilberg, O Bairey American journal of hematology 84 (6), 338-343, 2009 | 209 | 2009 |
| High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome–negative acute lymphoblastic leukemia S O'Brien, G Schiller, J Lister, L Damon, S Goldberg, W Aulitzky, ... Journal of clinical oncology 31 (6), 676, 2013 | 207 | 2013 |
